AR090466A1 - Solucion oftalmologica acuosa que contiene ciclosporina - Google Patents
Solucion oftalmologica acuosa que contiene ciclosporinaInfo
- Publication number
- AR090466A1 AR090466A1 ARP130100936A ARP130100936A AR090466A1 AR 090466 A1 AR090466 A1 AR 090466A1 AR P130100936 A ARP130100936 A AR P130100936A AR P130100936 A ARP130100936 A AR P130100936A AR 090466 A1 AR090466 A1 AR 090466A1
- Authority
- AR
- Argentina
- Prior art keywords
- polymers
- solution according
- solution containing
- polymer
- ophthalmic solution
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 2
- 108010036949 Cyclosporine Proteins 0.000 title abstract 2
- 229960001265 ciclosporin Drugs 0.000 title abstract 2
- 229930182912 cyclosporin Natural products 0.000 title 1
- 229940054534 ophthalmic solution Drugs 0.000 title 1
- 239000002997 ophthalmic solution Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 abstract 5
- 239000000243 solution Substances 0.000 abstract 4
- 239000003018 immunosuppressive agent Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940072106 hydroxystearate Drugs 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 229920001684 low density polyethylene Polymers 0.000 abstract 1
- 239000004702 low-density polyethylene Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una solución oftalmológica acuosa que contiene un agente inmunosupresor, tal como ciclosporina A, y al menos tres polímeros. Los tres polímeros son preferiblemente una combinación de un derivado de celulosa, un derivado polivinílico y un hidroxiestearato de macrogolglicerol. Reivindicación 27: Un vial de uso único o de múltiples dosis producidos en LDPE, caracterizado porque contiene la solución de acuerdo con la reivindicación 1. Reivindicación 28: Un método de tratamiento de un trastorno de la superficie del ojo de base inflamatoria o inmunológica caracterizado porque comprende administrar una solución de acuerdo con la reivindicación 1 en el ojo de un sujeto. Reivindicación 31: Un método de preparación de una solución de acuerdo con la reivindicación 1, caracterizado porque comprende los pasos de: solubilizar el inmunosupresor en la presencia de al menos una fracción del primer polímero en la presencia de agua; mezclar cualquier fracción remanente del primer polímero con los otros dos polímeros, agua y opcionalmente un sistema amortiguador y un agente de isotonicidad; y mezclar los productos obtenidos en los pasos anteriores.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614218P | 2012-03-22 | 2012-03-22 | |
| FR1252583A FR2988297B1 (fr) | 2012-03-22 | 2012-03-22 | Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090466A1 true AR090466A1 (es) | 2014-11-12 |
Family
ID=46298539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100936A AR090466A1 (es) | 2012-03-22 | 2013-03-21 | Solucion oftalmologica acuosa que contiene ciclosporina |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8969305B2 (es) |
| EP (1) | EP2827840B1 (es) |
| JP (1) | JP6166341B2 (es) |
| KR (1) | KR102021633B1 (es) |
| AR (1) | AR090466A1 (es) |
| BR (1) | BR112014019141A8 (es) |
| CA (1) | CA2863000C (es) |
| CL (1) | CL2014002271A1 (es) |
| CY (1) | CY1122086T1 (es) |
| DK (1) | DK2827840T3 (es) |
| ES (1) | ES2746701T3 (es) |
| FR (1) | FR2988297B1 (es) |
| HU (1) | HUE045252T2 (es) |
| LT (1) | LT2827840T (es) |
| MA (1) | MA37297B1 (es) |
| MX (1) | MX350799B (es) |
| PL (1) | PL2827840T3 (es) |
| PT (1) | PT2827840T (es) |
| RS (1) | RS59324B1 (es) |
| RU (1) | RU2634267C2 (es) |
| SI (1) | SI2827840T1 (es) |
| SM (1) | SMT201900638T1 (es) |
| UA (1) | UA115141C2 (es) |
| WO (1) | WO2013140071A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015093924A1 (es) * | 2013-12-19 | 2015-06-25 | CASTRO ALDRETE, Jorge Issac | Vehículo para la administración de compuestos farmacéuticos |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0558906A (ja) * | 1991-09-06 | 1993-03-09 | Sankyo Co Ltd | シクロスポリン点眼製剤 |
| EP0642332B1 (en) * | 1992-05-13 | 1997-01-15 | Sandoz Ltd. | Ophthalmic compositions containing a cyclosporin |
| US6254860B1 (en) * | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
| US7732404B2 (en) * | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| EP1142566B1 (fr) | 2000-04-07 | 2003-10-01 | Laboratoire Medidom S.A. | Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate |
| CN1127955C (zh) * | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | 一种眼前段及眼表免疫相关性疾病治疗药物 |
| TWI336257B (en) * | 2003-06-13 | 2011-01-21 | Alcon Inc | Ophthalmic compositions containing a synergistic combination of three polymers |
| US20060148686A1 (en) * | 2004-12-30 | 2006-07-06 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy |
| US20080146497A1 (en) * | 2006-07-25 | 2008-06-19 | Graham Richard S | Cyclosporin Compositions |
| US9561178B2 (en) * | 2006-07-25 | 2017-02-07 | Allergan, Inc. | Cyclosporin compositions |
| CA3014633C (en) * | 2007-10-08 | 2022-05-17 | Aurinia Pharmaceuticals Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors |
| EA019867B1 (ru) * | 2007-10-08 | 2014-06-30 | Фовея Фармасьютикалс | Водные офтальмологические препараты |
| BRPI0818483A2 (pt) * | 2007-11-01 | 2015-04-14 | Bausch & Lomb | Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma. |
| US20090286718A1 (en) * | 2008-01-04 | 2009-11-19 | Sirion Therapeutics, Inc. | Stable Aqueous Cyclosporin Compositions |
| CN101244035A (zh) * | 2008-02-21 | 2008-08-20 | 南京医科大学附属南京第一医院 | 一种环孢菌素a眼用乳剂制剂及其制备方法 |
| KR20120022574A (ko) * | 2010-07-30 | 2012-03-12 | 주식회사종근당 | 사이클로스포린 에이 함유 점안제 조성물 |
-
2012
- 2012-03-22 FR FR1252583A patent/FR2988297B1/fr active Active
-
2013
- 2013-03-12 US US13/796,392 patent/US8969305B2/en active Active
- 2013-03-15 CA CA2863000A patent/CA2863000C/fr active Active
- 2013-03-15 BR BR112014019141A patent/BR112014019141A8/pt not_active Application Discontinuation
- 2013-03-15 SI SI201331573T patent/SI2827840T1/sl unknown
- 2013-03-15 EP EP13715338.3A patent/EP2827840B1/fr active Active
- 2013-03-15 SM SM20190638T patent/SMT201900638T1/it unknown
- 2013-03-15 HU HUE13715338A patent/HUE045252T2/hu unknown
- 2013-03-15 LT LTEP13715338.3T patent/LT2827840T/lt unknown
- 2013-03-15 PL PL13715338T patent/PL2827840T3/pl unknown
- 2013-03-15 UA UAA201409442A patent/UA115141C2/uk unknown
- 2013-03-15 KR KR1020147024067A patent/KR102021633B1/ko not_active Expired - Fee Related
- 2013-03-15 MX MX2014010270A patent/MX350799B/es active IP Right Grant
- 2013-03-15 DK DK13715338.3T patent/DK2827840T3/da active
- 2013-03-15 RS RSP20191230 patent/RS59324B1/sr unknown
- 2013-03-15 WO PCT/FR2013/050557 patent/WO2013140071A1/fr not_active Ceased
- 2013-03-15 ES ES13715338T patent/ES2746701T3/es active Active
- 2013-03-15 JP JP2015500964A patent/JP6166341B2/ja not_active Expired - Fee Related
- 2013-03-15 RU RU2014134741A patent/RU2634267C2/ru active
- 2013-03-15 PT PT137153383T patent/PT2827840T/pt unknown
- 2013-03-21 AR ARP130100936A patent/AR090466A1/es not_active Application Discontinuation
-
2014
- 2014-08-19 MA MA37297A patent/MA37297B1/fr unknown
- 2014-08-27 CL CL2014002271A patent/CL2014002271A1/es unknown
-
2019
- 2019-09-26 CY CY20191101012T patent/CY1122086T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013140071A1 (fr) | 2013-09-26 |
| EP2827840A1 (fr) | 2015-01-28 |
| JP2015510921A (ja) | 2015-04-13 |
| FR2988297B1 (fr) | 2014-03-28 |
| JP6166341B2 (ja) | 2017-07-19 |
| CA2863000A1 (fr) | 2013-09-26 |
| MX2014010270A (es) | 2015-01-14 |
| FR2988297A1 (fr) | 2013-09-27 |
| MA37297B1 (fr) | 2017-01-31 |
| US20130267472A1 (en) | 2013-10-10 |
| UA115141C2 (uk) | 2017-09-25 |
| RU2014134741A (ru) | 2016-03-20 |
| MA37297A1 (fr) | 2016-05-31 |
| RU2634267C2 (ru) | 2017-10-24 |
| BR112014019141A8 (pt) | 2017-07-11 |
| EP2827840B1 (fr) | 2019-08-28 |
| KR20140136932A (ko) | 2014-12-01 |
| SMT201900638T1 (it) | 2020-01-14 |
| BR112014019141A2 (es) | 2017-06-20 |
| RS59324B1 (sr) | 2019-10-31 |
| CA2863000C (fr) | 2020-04-21 |
| HUE045252T2 (hu) | 2019-12-30 |
| US8969305B2 (en) | 2015-03-03 |
| LT2827840T (lt) | 2019-10-10 |
| PT2827840T (pt) | 2019-10-11 |
| SI2827840T1 (sl) | 2019-11-29 |
| CY1122086T1 (el) | 2020-11-25 |
| MX350799B (es) | 2017-09-25 |
| DK2827840T3 (da) | 2019-09-30 |
| PL2827840T3 (pl) | 2019-12-31 |
| CL2014002271A1 (es) | 2014-11-03 |
| ES2746701T3 (es) | 2020-03-06 |
| KR102021633B1 (ko) | 2019-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
| MX2018002723A (es) | Macrociclicos peptidomimeticos y usos de los mismos. | |
| CL2017000814A1 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. | |
| MX376113B (es) | Derivados de azabenzimidazoles como moduladores del receptor ampa, y el uso de los mismos en el tratamiento de enfermedades asociadas con los receptores ampa. | |
| CY1119435T1 (el) | Σκευασμα για αντισωμα εναντι- αλφα4βητα7 | |
| AR100334A1 (es) | Solución oftálmica acuosa y método para tratar el síndrome del ojo seco | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| CL2019000245A1 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos. | |
| BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
| MX2009006786A (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
| UY36465A (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| MX2015002239A (es) | Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares. | |
| MA38399A1 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| IN2013MU03583A (es) | ||
| EA201792487A1 (ru) | Композиции гидроксипропил-бета-циклодекстринов и способы | |
| ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| EP4360621A3 (en) | Formulations of bendamustine | |
| CY1116318T1 (el) | Μακροκυκλικη ενωση και μεθοδοι για την παραγωγη της | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| MX2016006318A (es) | 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso. | |
| MX382580B (es) | Formulaciones de liberación inmediata disuasivas de abuso que comprenden polisacáridos no celulósicos. | |
| CY1121852T1 (el) | Μορφοποιησεις και μεθοδοι παρασκευης μορφοποιησεων για χρηση στον καθαρισμο του παχεος εντερου | |
| CL2014002918A1 (es) | Derivados de espiro[2.4]heptano puenteados fluorados; composicion farmaceutica y uso como agonistas del receptor de alx en el tratamiento de enfermedades inflamatorias, alergicas. cardiovasculares, entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |